In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.
One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterizat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3285647?pdf=render |
| _version_ | 1819172918978936832 |
|---|---|
| author | Yasaman Ardeshirpour Victor Chernomordik Rafal Zielinski Jacek Capala Gary Griffiths Olga Vasalatiy Aleksandr V Smirnov Jay R Knutson Ilya Lyakhov Samuel Achilefu Amir Gandjbakhche Moinuddin Hassan |
| author_facet | Yasaman Ardeshirpour Victor Chernomordik Rafal Zielinski Jacek Capala Gary Griffiths Olga Vasalatiy Aleksandr V Smirnov Jay R Knutson Ilya Lyakhov Samuel Achilefu Amir Gandjbakhche Moinuddin Hassan |
| author_sort | Yasaman Ardeshirpour |
| collection | DOAJ |
| description | One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention. In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed (NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process, which can open a new paradigm in the "image and treat" concept, especially for early evaluation of the efficacy of the therapy. |
| first_indexed | 2024-12-22T20:14:49Z |
| format | Article |
| id | doaj.art-25b821c587e742b69e352a4ac1150e98 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T20:14:49Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-25b821c587e742b69e352a4ac1150e982022-12-21T18:13:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3188110.1371/journal.pone.0031881In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.Yasaman ArdeshirpourVictor ChernomordikRafal ZielinskiJacek CapalaGary GriffithsOlga VasalatiyAleksandr V SmirnovJay R KnutsonIlya LyakhovSamuel AchilefuAmir GandjbakhcheMoinuddin HassanOne of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention. In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed (NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process, which can open a new paradigm in the "image and treat" concept, especially for early evaluation of the efficacy of the therapy.http://europepmc.org/articles/PMC3285647?pdf=render |
| spellingShingle | Yasaman Ardeshirpour Victor Chernomordik Rafal Zielinski Jacek Capala Gary Griffiths Olga Vasalatiy Aleksandr V Smirnov Jay R Knutson Ilya Lyakhov Samuel Achilefu Amir Gandjbakhche Moinuddin Hassan In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PLoS ONE |
| title | In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. |
| title_full | In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. |
| title_fullStr | In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. |
| title_full_unstemmed | In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. |
| title_short | In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. |
| title_sort | in vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers |
| url | http://europepmc.org/articles/PMC3285647?pdf=render |
| work_keys_str_mv | AT yasamanardeshirpour invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT victorchernomordik invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT rafalzielinski invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT jacekcapala invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT garygriffiths invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT olgavasalatiy invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT aleksandrvsmirnov invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT jayrknutson invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT ilyalyakhov invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT samuelachilefu invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT amirgandjbakhche invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT moinuddinhassan invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers |